Evaluation of therapeutic effects of $^{125}$I particles brachytherapy for recurrent bladder cancer

YU-MING ZHOU, XIAO FENG, BING-CHENG ZHOU, YUE-FENG FAN and YUAN-LIANG HUANG

Department of Intervention Therapy, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000, P.R. China

Received January 23, 2017; Accepted September 4, 2017

DOI: 10.3892/ol.2017.7723

Abstract. The aim of the present study was to evaluate the clinical value of $^{125}$I particles implantation in the treatment of recurrent bladder cancer. The study is a retrospective analysis of 32 patients with recurrent bladder cancer treated between May 2010 and January 2010. Of these, 16 cases (chemotherapy group) received conventional chemotherapy. A total of 16 patients ($^{125}$I group) received radiotherapy with $^{125}$I particles, followed by conventional chemotherapy. By guidance of B ultrasound, $^{125}$I radioactive particles were implanted. All 32 patients were relieved after treatment, and the tumors were significantly reduced after 2 months. However, the tumors in the $^{125}$I group were significantly smaller than those in the chemotherapy group (P<0.05). The patients were followed-up for 1 year and no recurrence was found. Additionally, no complications occurred. Compared with the chemotherapy group, the tumor volume of the $^{125}$I group was significantly reduced (P<0.05). The disease-free survival and 5-year survival rates of the patients in the follow-up showed that the disease-free survival and 5-year survival rates of the patients in $^{125}$I group were significantly improved compared to those in the chemotherapy group. Therefore, the results have shown that $^{125}$I radioactive particles in the treatment of bladder cancer improve the symptoms of patients with bladder cancer in the short term, and continuously kill residual tumor and prevent recurrence.

Introduction

$^{125}$I particles are capable of releasing X-ray and gamma-rays in the process of decay, through in vivo implantation for continuous internal radiation therapy. These particles have the ability to inhibit tumor cell proliferation and induce apoptosis. $^{125}$I has a low dose rate, high relative biological effect, appropriate radius of killing, and is used widely in the treatment of a variety of malignant tumors, showing obvious advantages in the local control and survival rate of patients (1,2). With the rapid development of molecular biology, modern advanced biology techniques have been used to study the mechanism of tumorigenesis and prognosis, and the treatment of malignant tumors with $^{125}$I particles is no exception. Through a lot of basic research, the molecular mechanism of $^{125}$I particles in radiotherapy for malignant tumor has achieved certain results in the induction of tumor cell apoptosis and cell cycle arrest, intracellular signal transduction and inhibition of tumor angiogenesis. In patients with recurrent bladder cancer, the efficacy of the general chemotherapy regimen is limited (3). In this study, we implanted $^{125}$I radioactive particles into the tumor, and observed the clinical efficacy of this treatment modality during recurrent bladder cancer.

Materials and methods

General. A total of 16 patients with recurrent bladder cancer treated with $^{125}$I, there were 13 males and 3 females, aged 47-69 years , and the average was 59.2±3.28 years. Of the 16 cases, 10 cases were diagnosed as transitional cell carcinoma, 1 case was squamous cell carcinoma, and 5 cases were hamartoma. All 16 patients had hematuria, urinary frequency and urgency symptoms, and 1 patient had dysuria. In the chemotherapy group, there were 14 males and 2 females, aged 43-65 years, with an average age of 58.3±2.33 years. Of these, 8 cases were transitional cell carcinoma, 4 cases were squamous cell carcinoma, and 4 cases were hamartoma. All 16 patients had hematuria, urinary frequency and urgency symptoms. There was no significant difference in age between the two groups. There was no significant difference in pathological types and the number of complications by the Chi-square test (P>0.05) (Table I).

The present study has been approved by the Ethics Committee of The First Affiliated Hospital of Xiamen University (Fujian, China). Informed consents were signed by the patients and/or guardians.

Correspondence to: Dr Xiao Feng, Department of Intervention Therapy, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, Fujian 361000, P.R. China E-mail: nexia1501276zhis@163.com

Key words: advanced bladder cancer, iodine particles implantation
active $^{125}\text{I}$ particle source was obtained from the American SynQor Inc. (Boxborough, MA, USA), and the activity of each particle was 0.40-0.50 mCi, with a half-life of 60.1 days; gamma-ray energy of 27,35 kEV; and tissue penetration distance of 1.7 cm.

**Methods.** To determine the range of tumor surface markers measured by B ultrasound, combined with the TPS planning system, the grid was drawn using the pitch 1.0 cm square matrix. Each intersection of the grid served as the access channel. After local routine disinfection, an ultrasonic probe navigation frame was fixed to the edge of the tumor. From this point, the needle was taken up to 1 cm from the edge of the tumor, the first particle was planted, and the needle was withdrawn 1 cm. The second particle was planted, up to 1 cm from the edge of the tumor, the last particle of the channel was planted, and the replacement of the channel continued to grow. A postoperative indwelling catheter was left, with regular bladder irrigation, antibiotics were taken to prevent infection, and hemostasis and other symptomatic treatments were taken. Tumor sites and the number of implants of $^{125}\text{I}$ group are presented in Table II.

**Chemotherapy regimen.** Both groups of patients were treated with internal iliac artery chemotherapy for the first time within 2 weeks after surgery, and the second internal iliac artery chemotherapy was performed within 1 month after surgery in the two groups. The chemotherapeutic drugs Pharmorubicin 30 mg/m$^2$ (surface area) was taken each time. The Seldinger technique was used to puncture one side of the femoral artery, and internal iliac artery angiography was taken on both sides to observe the blood supply of the bladder. The catheter was placed into the internal iliac artery of the affected side, and 2/3 of the drug was injected. Then the catheter was placed into the contralateral internal iliac artery, and the remaining 1/3 of the drug was injected. Following chemotherapy, hydration, alkalinization and hepatoprotective treatments were taken.

**Curative effect judgment.** According to the improvement of clinical symptoms, the changes of tumor size by the re-examination of B-ultrasound or CT and CT review after 17 months, the curative effect was evaluated.

**Statistical analysis.** The collected data were processed using SPSS 15.0 statistical software (SPSS, Inc., Chicago, IL, USA). Measurement data were presented as mean ± SD. An independent sample t-test was used for comparison between groups. Countable data were expressed by case number or constituent ratio, and tested using the Chi-square test. The log-rank test

---

**Table I. Comparison of general clinical data.**

| Variables             | No. of cases | Sex (male/female) | Age (years) | Transitional cell carcinoma | Squamous cell carcinoma | Hamartoma |
|-----------------------|-------------|-------------------|-------------|-----------------------------|-------------------------|-----------|
| $^{125}\text{I}$ group | 16          | 13/3              | 59.2±3.28   | 10                          | 1                       | 5         |
| Chemotherapy group    | 16          | 14/2              | 58.3±2.33   | 8                           | 4                       | 4         |
| $\chi^2$ value        | -           | 0.43              | 0.22        | 0.83                        |                         |           |
| P-value               | -           | 0.59              | 0.78        | 0.18                        |                         |           |

**Table II. Tumor location and number of implanted particles.**

| No. | Age | Tumor location | Tumor size (cm$^3$) | No. of particles |
|-----|-----|----------------|---------------------|-----------------|
| 1   | 58  | Right anterior wall of bladder | 21.2              | 40              |
| 2   | 57  | Right posterior wall of bladder | 9.2               | 20              |
| 3   | 54  | Right anterior wall of bladder | 9.8               | 20              |
| 4   | 59  | Right anterior wall of bladder | 4.8               | 9               |
| 5   | 53  | Left posterior wall of bladder | 10.2              | 20              |
| 6   | 50  | Left posterior wall of bladder | 11.3              | 20              |
| 7   | 49  | Posterior wall and right wall of bladder | 20.3             | 40              |
| 8   | 63  | Right anterior wall of bladder | 12.5              | 20              |
| 9   | 52  | Right posterior wall of bladder | 3.8               | 9               |
| 10  | 53  | Right anterior wall of bladder | 4.4               | 9               |
| 11  | 54  | Posterior wall and right wall of bladder | 5.4              | 9               |
| 12  | 59  | Posterior wall and right wall of bladder | 5.7              | 9               |
| 13  | 61  | Right wall of bladder          | 7.8               | 10              |
| 14  | 60  | Left and right posterior wall of bladder | 9.8              | 20              |
| 15  | 58  | Right posterior wall of bladder | 9.6               | 20              |
| 16  | 69  | Posterior wall and right wall of bladder | 3.5              | 9               |
and COX multivariate analysis were used to analyze the prognosis of the patients. A P<0.05 was considered to indicate a statistically significant analysis.

**Results**

**Changes of tumor volume before and after treatment.** We analyzed the tumor volume of the two groups before and after treatment by CT. The results showed that the tumor volume of the two groups of patients after treatment was significantly reduced. The tumor volume of the $^{125}$I group was 9.33±5.27 before treatment, while it reduced to 3.44±1.23 after treatment. The tumor volume of patients in the chemotherapy group was 9.21±1.23 before treatment and 6.57±2.17 after treatment. However, compared with the chemotherapy group, the tumor volume of the $^{125}$I group was significantly reduced (P<0.05) (Table III).

**Comparison of survival prognosis.** Concerning the survival prognosis of the two groups, we found that compared with the chemotherapy group, the $^{125}$I group had a significantly higher survival rate of five years (P<0.05). Disease-free survival was significantly prolonged (P<0.05). The difference was statistically significant (P<0.05) (Figs. 1 and 2).

**Discussion**

Bladder cancer is one of the most common malignant tumors in the urinary system. The key to treatment is to control the recurrence and metastasis of the local tumor through multidisciplinary efforts (4-6). For nearly half a century, the academic community has made noteworthy progress in the comprehensive treatment of surgery, radiotherapy and chemotherapy. However, the recurrence rate within a few years after tumor resection is 50-80% and invasive evolution accounts for 50-80% in recurrent cases (7). Although radical cystectomy is widely accepted, there is currently no evidence that surgery is more effective than radiotherapy. Furthermore, radiotherapy may retain the bladder, especially in improving the quality of life of patients as it has greater advantages (8). Although there are certain effects of external radiotherapy, the loss of normal tissue is serious and the quality of life is also reduced. Moreover, it has side effects and high equipment costs.

Brachytherapy was performed by implanting radioactive sources into the hollow organs (intracavitary radiotherapy) or directly implanted in the tumor tissue (interstitial brachytherapy). A short range of treatment ranging from approximately 5 mm to 5 cm characterizes it. Additionally, the radiation dose is mainly concentrated in a small part of the tumor tissue and surrounding normal tissue (9). High-dose irradiation can be obtained in the treatment of brachytherapy and the surrounding normal tissues may be well protected (10). Brachytherapy is one of the main treatments of bladder cancer and prostate cancer (11). The physical half-life of the radioactive element $^{125}$I particles is 59.6 days, with the energy of 27.4-31.5 Kev X-rays and 35.5 Kev gamma-rays (12). When the $^{125}$I particles were implanted into the tumor focus and the

| Variables         | Number of cases | Before treatment | After treatment | T-value | P-value |
|-------------------|-----------------|------------------|----------------|---------|---------|
| $^{125}$I group   | 16              | 9.33±5.27        | 3.44±1.23      | 2.18    | 0.02    |
| Chemotherapy group| 16              | 9.21±1.23        | 6.57±2.17      | 3.28    | 0.012   |
| T-value           | -               | 0.27             | 3.49           | -       | -       |
| P-value           | -               | 0.79             | 0.003          | -       | -       |

Figure 1. Survival curve. After follow-up, the survival rate of 5 years of the $^{125}$I group was significantly lower than that of the chemotherapy group, and the difference was statistically significant between the two groups (Z=12.22, P<0.05).

Figure 2. Progression-free survival. After 5 years of follow-up, compared with the chemotherapy group, the progression-free survival was significantly prolonged in the $^{125}$I group, and the difference was statistically significant (Z=12.22, P<0.05).
lymphatic system, the particles were scattered with low energy X-rays and gamma-rays. Tumor proliferation was significantly reduced by continuous irradiation (13). At the same time, continuous low energy irradiation inhibits tumor mitosis, with the tumor cell concentration in the G2 phase, resulting in tumor cell killing by radiation effect to the maximum, to effectively inhibit tumor cell proliferation and cytothesis, in order to achieve the purpose of cure (14). Furthermore, 125I particles are not involved in metabolism, and cause little damage to the patients and medical staff (15). In particular, according to the intraoperative situation, targeted at a certain location, tumor cells are directly killed at different stages of the cell cycle (16). However, conventional external irradiation is short-time high-intensity fractionated irradiation, which could kill the M cells. This is often terminated because the patient could not tolerate the radiation reaction (17). Interstitial implantation of radioactive 125I particles brachytherapy is a minimally invasive treatment technology developed in previous years, showing a good therapeutic effect in the clinical practice of treating multiple cancers with high efficiency and few side effects (18).

Brachytherapy is primarily used for the treatment of bladder and prostate cancer (19). However, to the best of our knowledge, there is no report on the application of 125I particles implantation in the treatment of bladder cancer (20). Our results have shown that 125I particles were implanted into the lesion or in the tissue for the treatment of bladder cancer, and the local recurrence rate was low. At the same time, the unresectable cancer tissue or the remaining tissue was directly radiated (21). Our study found that tumor volume measurement and statistical analysis in the CT of the two groups of patients before and after treatment were significantly reduced as compared with prior to treatment. However, compared with the chemotherapy group, the tumor volume of 125I group was significantly reduced. Following a comparison of the survival prognosis of the two groups, we found that compared with the chemotheraphy group, the 125I group had a significantly higher survival rate of 5 years (P<0.05). Disease-free survival was significantly prolonged (P<0.05). The results showed that 125I particle radiation therapy has good clinical efficacy in clinical life therapy and survival prognosis of recurrent bladder cancer patients.

125I particle implantation-assisted radiotherapy for the treatment of bladder cancer is optimal compared to in vitro irradiation treatment, and especially applicable to patients for whom surgery is not possible. 125I particles are capable of killing the tumor cells directly, and are not affected by the oxygen content in tumor cells (22,23). Owing to the accurate localization, the local effective dose is large, but the radiation distance is small, the radiation damage is slight, and there is no obvious adverse effect on the surrounding tissue. Therefore, the side effects are small and have no significant influence on the quality of life (24). We believe that the treatment of bladder cancer by 125I particles brachytherapy is more advantageous than that of in vitro irradiation. It has the following advantages (25-29): i) The radioactive source is small, the half-life is short (only 60 days), the energy is low, and the killing radius is not more than 2 cm; ii) the operation is simple, the 125I particle source may be implanted into the tissue under direct vision, the accuracy of the treatment is improved, and the range of the surgical injury is reduced; iii) the accuracy rate of the cancer tissue is high, and the continuous emission of pure gamma-ray can effectively hit the mitotic phase of the cancer cell. The continuous low-dose irradiation inhibits the mitosis of the tumor cells, and the curative effect is good; and iv) it may effectively improve the dose distribution ratio of tumor and normal tissue.

In conclusion, we believe that 125I radioactive particles in the treatment of bladder cancer may not only improve the symptoms of patients with bladder cancer in the short term, rapidly reduce the tumor, but also continuously kill residual tumor and prevent recurrence of the tumor.

References
1. Ohga S, Nakamura K, Shiroyama Y, Tatsugami K, Sasaki T, Nomoshita T, Yoshitake T, Asai K, Hirata H, et al: Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer. J Radiat Res 55: 1178-83 2014.
2. Andrieu C, Pond G, Webster D, McLean M, Gillan C and Crook J: Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 5: 9-13, 2006.
3. Arias F, Dueñas M, Martínez E, Domínguez MA, Illarramendi JI, Villanueva E, Tejedor M, Molina F, Meiriño R and Valderi JJ: Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle. Cancer 80: 115-120, 1997.
4. Li Y, Lin K, Yang Z, Han N, Quan X, Guo X and Li C: Bladder cancer stem cells: Clonal origin and therapeutic perspectives. Oncotarget 8: 66666-66679, 2017.
5. Radford IR and Aldridge DR: Importance of DNA damage in the induction of apoptosis by ionizing radiation: Effect of the scid mutation and DNA ploidy on the radiosensitivity of murine lymphoid cell lines. Int J Radiat Biol 75: 143-153, 1999.
6. Ohga S, Nakamura K, Shiroyama Y, Tatsugami K, Sasaki T, Nomoshita T, Yoshitake T, Asai K, Hirata H, et al: Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer. J Radiat Res 55: 1178-1183, 2014.
7. Prada PJ, Hevia M, Juan G, Abascal JM, de la Rúa A, Abascal R, Fernández J and Rodríguez R: 125I Low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years. Arch Esp Urol 58: 213-226, 2005 (In Spanish).
8. Lucerna M, Pomije J, Mchetchiariako D, Kadl A, Gruber F, Bilban M, Sobanov Y, Schabbauer G, Breuss J, Wagner O, et al: Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res 66: 6708-6713, 2006.
9. Prada PJ, Hevia M, Juan G, Abascal R, Fernández J and Rodríguez R: Low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years. Arch Esp Urol 58: 213-226, 2005 (In Spanish).
10. Wu MY, Wu XY, Li QS and Zheng RM: Expression of Egr-1 gene and its correlation with the oncogene proteins in non-irradiated and irradiated esophageal squamous cell carcinoma. Dis Esophagus 19: 267-272, 2006.
11. Wu MY, Wu XY, Li QS and Zheng RM: Expression of Egr-1 gene and its correlation with the oncogene proteins in non-irradiated and irradiated esophageal squamous cell carcinoma. Dis Esophagus 19: 267-272, 2006.
12. Cao XF, He XT, Ji L, Xiao J and Lv J: Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 22: 477-481, 2009.
13. Wu MY, Wu XY, Li QS and Zheng RM: Expression of Egr-1 gene and its correlation with the oncogene proteins in non-irradiated and irradiated esophageal squamous cell carcinoma. Dis Esophagus 19: 267-272, 2006.
14. Gassmann M, Chinov D and Wenger RH: Regulation of the hypoxia-inducible factor-1 alpha. ARNT is not necessary for hypoxic induction of HIF-1 alpha in the nucleus. Adv Exp Med Biol 475: 87-99, 2000.
15. Sjöström A, Bae P, Malmström P and Carlsson J: Binding of 125I after administration of 125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer spheroids. Int J Oncol 17: 559-564, 2000.
16. Sjöström A, Bae P, Malmström PU, Nilsson S and Carlsson J: Binding, internalization and degradation of EGF-dextran in conjugates in two human bladder-cancer cell lines. Int J Cancer 70: 383-389, 1997.
17. Mariani G, Collecchi P, Baldassarri S, Di Luca L, Burlati S, Fontanini G, Baranowska-Kortylewicz J, Adelstein SJ and Kassl AI: Tumor uptake and mitotic activity pattern of [5-125I] iododeoxyuridine after intratumoral infusion in patients with bladder cancer. J Nucl Med 37: 16-19, 1996.
17. Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ and Kassis AI: Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med 37: 315-320, 1996.

18. Colpi GM, Fanciullacci F, Beretta G, Negri L and Zanollo A: Evoked sacral potentials in subjects with true premature ejaculation. Andrologia 18: 583-586, 1986.

19. Xin ZC, Choi YD, Rha KH and Choi HK: Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol 158: 451-455, 1997.

20. Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ and Choi HK: Penile sensitivity in patients with primary premature ejaculation. J Urol 156: 979-981, 1996.

21. Smith K, Fennelly JA, Neal DE, Hall RR and Harris AL: Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 49: 5810-5815, 1989.

22. Tamura K, Araki F and Ohno T: SU-F-T-46: The effect of inter-seed attenuation and tissue composition in prostate 125I brachytherapy dose calculations. Med Phys 43: 3471-3472, 2016.

23. Tan Q, Qin Q, Yang W, Lian B, Mo Q and Wei C: Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study. Medicine (Baltimore) 95: e5302, 2016.

24. Jeon J, Shim HE, Mushtaq S, Choi MH, Park SH, Choi DS and Jung BS: An optimized protocol for the efficient radiolabeling of gold nanoparticles by using a 125I-labeled azide prosthetic group. J Vis Exp: e54759, 2016.

25. Jiao D, Wu G, Ren J and Han X: Radiofrequency ablation versus 125I-seed brachytherapy for painful metastases involving the bone. Oncotarget 7: 87523-87531, 2016.

26. Becker S, Schlederer T, Kramer MF, Haack M, Vrtala S, Resch Y, Lupinek C, Valenta R and Gröger M: Real-life study for the diagnosis of house dust mite allergy - the value of recombinant allergen-based IgE serology. Int Arch Allergy Immunol 170: 132-137, 2016.

27. Sheikholeslami S, Nedaie HA, Sadeghi M, Pourbeigiy H, Shahzadi S, Zehadian M, Hasani M and Meigooni AS: Monte Carlo calculations and experimental measurements of the TG-43U1-recommended dosimetric parameters of 125I (Model IR-Seed2) brachytherapy source. J Appl Clin Med Phys 17: 430-441, 2016.

28. Asadi S, Vaez-Zadeh M, Vahidian M, Marghchouei M and Masoudi SF: Ocular brachytherapy dosimetry for 103Pd and 125I in the presence of gold nanoparticles: A Monte Carlo study. J Appl Clin Med Phys 17: 90-99, 2016.

29. Sugawara A1, Nakashima J, Shigematsu N, Kunieda E, Kubo A: Prediction of seed migration after transperineal interstitial prostate brachytherapy with 125I free seeds. Brachytherapy 8: 52-56, 2009.